Mucosis’ research efforts are centered around the development of vaccines that are administered to the mucosal layers e.g. those of the nose and mouth, with the intent to raise both a systemic and a strong local immune reaction that efficiently prevents invasion of pathogens into the body. To achieve this, we have developed the unique technology Mimopath® that we use to re-formulate existing vaccines such that they, for example, can be given to humans with a simple nose spay instead of an intramuscular injection. Our current focus is on the development of vaccines that prevent diseases caused by respiratory tract pathogens. In addition, we employ our technology to develop new vaccines that address other unmet medical needs.